Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA ...
After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...
On the Netflix crime comedy, Dan Levy’s character is supposed to be clueless about fashion—but his roomy khakis and rumpled ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc.
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Arturo Molina sold 9,514 directly on Jan. 20, 2026, generating a transaction value of approximately $784,700 at a reported price of $82.48 per share. This sale represented 8.91% of Dr. Molina’s direct ...
Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results